Clinical trials: Biphasic Mesothelioma
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma.
- Conditions
- Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8
- Trial name
- NCT04158141
- Testing
- Carboplatin, Cisplatin, Decortication
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- NRG Oncology
Biphasic Mesothelioma, Epithelioid Mesothelioma
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma.
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
- Trial name
- NCT03228537
- Testing
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy
- Where
- 174 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma
Pembrolizumab in Treating Patients With Malignant Mesothelioma
This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum).
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma
- Trial name
- NCT02399371
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Chicago